Genomics and AI to Predict Cancer Treatment
Integrating genomics and artificial intelligence to predict treatment responses in cancer patients is going to become a reality. A major collaborative research project “Artificial Intelligence and Genomics to Predict Cancer Treatment” has been awarded a $2.6 million CRC-P Grant (Cooperative Research Centre Projects) by Australian Government. The official announcement is made today by Assistant Minster for Science, Jobs and Innovation, Zed Seselja, and Federal Member for Brisbane, Trevor Evans on 25 Jul 2018.
BGI is the Next-Gen Sequencing partner of the Project, in collaboration with other world leading partners including Max Kelsen the leading partner specialised in artificial intelligence technology, QIMR Berghofer Medical Research Institute as the research partner, Queensland Health Metro North Hospital and Health Service as the clinical partner, and genomiQa as the bioinformatic analysis partner.
The Project will receive $2.6 million under the fifth round of the CRC-P Program, and has attracted $6.4 million of cash and in-kind contributions from industry partners. "This project will firmly establish the role of artificial intelligence and whole genome analysis in the future of precision medicine" said Nicholas Therkelsen-Terry CEO of Max Kelsen.
Colin Albert, CEO of genomiQa, a spin-out company of QIMR Berghofer Institute of Medical Research said the project would help to unlock the value of whole genome data for patients and clinicians. “This project will firmly establish the role of whole genome analysis and artificial intelligence to help predict the response of immunotherapy for the treatment of cancer.”
Mr Albert said genomiQa’s high-quality genomic pipeline was developed by founders Dr Nic Waddell and Dr. John Pearson.
Dr. Bicheng Yang, Director of BGI Australia said, “BGI is proud to provide sequencing support for this $9.1 million project, which will help establish whole genome sequencing as part of routine clinical practice, as BGI’s objective is to make sequencing more affordable and accessible to benefit the general public”. More in the News
BGI Sequencers receive CFDA Certification
MGI, the manufacturing subsidiary under BGI Corporation, has received China Food and Drug Administration (CFDA) certification for its latest two models of next generation genetic sequencers. MGISEQ-2000 and MGISEQ-200 sequencers have been granted the Medical Device Registration Certificate (MDRC) by CFDA on 25th June 2018. MGI is the first organisation in China to receive the certification from CFDA for next-generation sequencing diagnostic products and medical devices. These two new sequencers will not just play an important role in scientific rsearch, but also contribute to a wide range of applications in the clinical medicine industry. Healthcare organisations will now have the confidence using the world’s leading sequencing solution to perform whole genome sequencing (WGS). MGISEQ-2000 supports two different types of Flow Cells and provides an independent dual Flow Cell operating platform. Users can combine dozens of different operating modes to provide more diversified options for sequencing. It can produce 1080G of high-quality sequencing data, and in PE100 mode at a full load MGI-2000 can provide single end-to-end sequencing within 48 hours. MGISEQ-200 is an instrument of convenience and flexibility. It takes less than 48 hours to produce 60G of high-quality sequencing data while functioning in PE100 mode at a full load. MGISEQ-200 can complete rapid tests of 24 tumor samples in one day.
Learn More
As a subsidiary of BGI, MGI adheres to BGI’s mission of genomics technology for the benefit of human beings, focusing on the Research& Development, manufacturing, production, and sales of life science and healthcare instruments and equipment, reagent materials and other relevant products. Since its acquisition of Complete Genomics, MGI has built upon the technologies to rapidly develop a new series of genetic sequencers.
BGI Events
